Lifordi Immunotherapeutics

Lifordi Immunotherapeutics is an early-stage biotech company translating the proven oncology success of antibody-drug conjugates (ADCs) into novel treatments for autoimmune and inflammatory diseases. The company's platform targets a highly internalized cell surface protein on myeloid and lymphoid cells to deliver therapeutic payloads directly to pathogenic immune cells. Backed by top-tier venture capital firms and led by an experienced management team, Lifordi is advancing its lead candidate, LFD-200, through Phase 1 trials in Rheumatoid Arthritis, aiming to establish a new paradigm in immunology therapeutics.

Novel, targeted antibody-drug conjugate (ADC) platform designed to deliver therapeutic payloads to pathogenic myeloid and lymphoid cells via a highly internalized cell surface membrane protein.

Lifordi is a first-mover in applying ADC technology specifically to autoimmunity, creating a novel competitive niche. However, it competes indirectly with all developers of RA and autoimmune therapies, including major pharma companies with deep resources. A few biotechs are exploring related targeted approaches (e.g., bispecifics, radioligands), but ADCs remain a distinct and less crowded strategy.